This article is more than 5 years old. Information may no longer be current.
Topical EV06 improves near vision in patients with presbyopia
Click Here to Manage Email Alerts
Twice-daily treatment with one drop of EV06 ophthalmic solution 1.5% improved distance-corrected near vision acuity efficacy measures when compared to placebo in a phase 1/2 study.
EV06 targets presbyopia by restoring crystalline lens flexibility, thereby allowing the lens to focus on nearby objects, according to a press release from Encore Vision.
By day 91, 82% of 50 patients using EV06 had 20/40 distance-corrected near vision acuity (DCNVA) or better, compared to 48% of the 25 patients using placebo. Baseline DCNVA values were 30% and 28%, respectively.
Sixty percent of EV06 subjects had 20/32 DCNVA or better at day 91 compared to 21% in the placebo group.
In the EV06 treatment group, DCVNA significantly improved from baseline as early as day 15, according to the release. At baseline, logMAR was 0.397 in the EV06 group and improved to 0.206 at day 91.
A significant proportion of subjects treated with EV06 gained 10 or more letters by day 15, compared to none in the placebo group.
A follow-up study at day 120 and day 270 post-treatment is now underway to assess the duration of EV06 treatment among participants from the previous study, according to Bill Burns, president and CEO, Encore Vision, in the press release.
“The positive results in favor of EV06 across multiple safety and efficacy endpoints provide a positive step forward in the development of the first ophthalmic drop addressing the root cause of presbyopia,” Richard L. Lindstrom, MD, Primary Care Optometry News Editorial Board member, said in the release. – by Abigail Sutton